Document is current
Any future updates will be listed below
-
Authors
Morice, Pierre-Marie https://orcid.org/0000-0002-9313-2701
Khalife-Hachem, Sabine
Sassier, Marion
Lelong-Boulouard, Véronique
Danu, Alina
Pasquier, Florence
Renneville, Aline https://orcid.org/0000-0003-0805-9640
Dolladille, Charles https://orcid.org/0000-0003-0449-6261
Micol, Jean-Baptiste https://orcid.org/0000-0003-0934-294X
- License Information
-
More Information
Article History
Received: 30 July 2024
Revised: 19 September 2024
Accepted: 23 September 2024
First Online: 14 October 2024
Competing interests
: Dr. MICOL reports personal fees from Jazz Pharmaceuticals, from Astellas Pharma, from Servier, from AbbVie, from Gilead Sciences, from AstraZeneca, outside the submitted work. All other authors declare no competing interests.
: The systematic review of randomized controlled trials was performed in accordance to the PRISMA Harms Checklist guideline. No ethics committee approval or subject informed consent was obtained as this was a retrospective analysis of already published studies. The pharmacovigilance study in VigiBase® was approved by the Caen University Hospital Research Ethics Committee (#2646).
